Compare Crispr Therapeutics AG (CRSP) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs KB Financial Group, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while KB Financial Group, Inc. trades at $117.53 (market cap $41.21B). The key difference: KB Financial Group, Inc. is far larger — about 7.9× Crispr Therapeutics AG's market cap, and KB Financial Group, Inc. pays a 2.67% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | KB | |
|---|---|---|
Market Cap | $5.23B | $41.21B |
Sector | Health | Financials |
52-Week High | $76.78 | $124.01 |
52-Week Low | $44.34 | $77.50 |
Enterprise Value | $3.65B | — |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
KB Financial trades at $117.85, down 2.39% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.36, P/B of 0.98, and net income margin of 27.82%. Recent earnings beats in Q1 and Q2 2026 highlight operational strength, while cash flow trends show variability with a net inflow of $4.41T in 2025.
The outlook is positive given earnings momentum and undervaluation relative to peers, but risks include volatile cash flows and dependence on interest rates. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism for upside potential amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
